ArticleJournal of the American Heart Association2023
Safety of Catheter Ablation Therapy for Atrial Fibrillation in Cardiac Amyloidosis.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Catheter Ablation for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta-Analysis.Journal of arrhythmia · 2026Article
- Proper Use of the National Inpatient Sample Database to Analyze Safety of Cardiovascular Procedures.Journal of the American Heart Association · 2026Article
- Outcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias.Heart rhythm O2 · 2025Article
- Catheter ablation of atrial fibrillation in patients with cardiac amyloidosis and sarcoidosis: procedural findings and outcomes.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Response to Letter to the Editor from Drs. Naoya Kataoka and Teruhiko Imamura.Heart and vessels · 2025Article
- Prevalence of Atrial Fibrillation and Intervention Therapy in Cardiac Amyloidosis.Reviews in cardiovascular medicine · 2025Review
- Anatomical characteristics of mitral isthmus and its spatial relationship with the esophagus in patients undergoing atrial fibrillation ablation using CT angiography.Frontiers in cardiovascular medicine · 2025Article
- Efficacy and safety of catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis: a systematic review and meta-analysis.Archives of medical sciences. Atherosclerotic diseases · 2025Review
- Arrhythmic Risk Stratification in Cardiac Amyloidosis: A Review of the Current Literature.Journal of cardiovascular development and disease · 2024Review
- Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: From Clinical Management to Catheter Ablation Indication.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Despite the high burden of atrial fibrillation in cardiac amyloidosis (CA), the safety of catheter ablation therapy in CA is not well established. We sought to examine short-term safety outcomes following atrial fibrillation ablation in patients with CA compared with matched patients with dilated cardiomyopathy (DCM). Methods and Results Using data from the National Inpatient Sample, we identified all hospitalizations for atrial fibrillation ablation from the fourth quarter of 2015 through 2019. Admissions for CA and DCM were matched in a 1:5 ratio using propensity scores based on the following sociodemographics: age, sex, race or ethnicity, payor, median income, comorbidities, and hospital characteristics. We compared in-hospital outcomes between both cardiomyopathies. We identified 1395 unweighted hospitalizations (representing 6750 national hospitalizations) for atrial fibrillation ablation, out of which 45 (3.2%) were admissions for CA. Compared with DCM, patients with CA were older (72.9 versus 65.1 years), had a higher burden of prior stroke (20.0% versus 8.6%) and chronic kidney disease (53.3% versus 33.6%), and were less likely to have a prior implantable cardioverter-defibrillator (4.4% versus 23.0%). We successfully matched 42 CAs to 210 DCM hospitalizations. After matching, there was no difference in total complications (14.3% versus 10.5%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.